SELLAS Life Sciences (SLS) Return on Capital Employed Growth (1y) (2013 - 2026)

SELLAS Life Sciences (SLS) Return on Capital Employed Growth (1y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 1,648.00
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 31,429.00
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 1,805.00
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 2,503.00
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -105.00
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -3,457.00
10 SELLAS Life Sciences 1.89 Bn 1.78 Bn - 10,252.00

Historic Data

Download Data
DateValue
Mar 31, 2026 10,252.00
Dec 31, 2025 18,534.00
Sep 30, 2025 24,651.00
Jun 30, 2025 35,178.00
Mar 31, 2025 393,586.00
Dec 31, 2024 -80,945.00
Sep 30, 2024 213,864.00
Jun 30, 2024 -9,561.00
Mar 31, 2024 -368,975.00
Dec 31, 2023 110,251.00
Sep 30, 2023 -219,340.00
Jun 30, 2023 -5,424.00
Mar 31, 2023 -8,171.00
Dec 31, 2022 -43,398.00
Sep 30, 2022 -21,628.00
Jun 30, 2022 -25,977.00
Mar 31, 2022 -26,135.00
Dec 31, 2021 -807.00
Sep 30, 2021 12,382.00
Jun 30, 2021 14,619.00